Dementia

Questioning why SVD progression is only observed in some patients 1:01
Questioning why SVD progression is only observed in some patients
Anil Tuladhar • 1 Sep 2021
Alpha-synuclein pathology: dangerous mitochondrial interactions 1:57
Alpha-synuclein pathology: dangerous mitochondrial interactions
Tiago Outeiro • 31 Aug 2021
CSF biomarkers for the early diagnosis of Alzheimer’s disease 2:40
CSF biomarkers for the early diagnosis of Alzheimer’s disease
Alberto Lleó • 1 Sep 2021
CSF biomarkers versus blood biomarkers for the early diagnosis of Alzheimer’s disease 0:50
CSF biomarkers versus blood biomarkers for the early diagnosis of Alzheimer’s disease
Alberto Lleó • 1 Sep 2021
SVD disrupts structural networks in the brain which can lead to dementia 1:04
SVD disrupts structural networks in the brain which can lead to dementia
Anil Tuladhar • 1 Sep 2021
Detection of covert brain lesions in patients with SVD using MRI scans 2:55
Detection of covert brain lesions in patients with SVD using MRI scans
Anil Tuladhar • 1 Sep 2021
Unveiling the mechanisms behind cognitive impairment and dementia in patients with SVD 1:33
Unveiling the mechanisms behind cognitive impairment and dementia in patients with SVD
Anil Tuladhar • 1 Sep 2021
HEAT-Net 2021 – Frontiers in neurodegeneration: what’s to come? 3:27
HEAT-Net 2021 – Frontiers in neurodegeneration: what’s to come?
Tiago Outeiro • 31 Aug 2021
What will be discussed at HEAT-Net 2021? 1:24
What will be discussed at HEAT-Net 2021?
Tiago Outeiro • 31 Aug 2021
The AMBAR project: from rationale to Phase III RCT 10:13
The AMBAR project: from rationale to Phase III RCT
Mercè Boada • 20 Jul 2021
Reduced cognitive decline in the AMBAR trial of plasma exchange with albumin replacement for AD 17:02
Reduced cognitive decline in the AMBAR trial of plasma exchange with albumin replacement for AD
Mercè Boada • 20 Jul 2021
The first AMBAR center: towards therapy commercialization 4:23
The first AMBAR center: towards therapy commercialization
Mercè Boada • 20 Jul 2021
Biomarkers for Alzheimer’s disease: past, present and future 3:18
Biomarkers for Alzheimer’s disease: past, present and future
Femke Bouwman • 1 Jul 2021
Challenges in biomarker development for Alzheimer’s disease 1:55
Challenges in biomarker development for Alzheimer’s disease
Femke Bouwman • 1 Jun 2021
Sleep disorders and neurodegeneration: which comes first? 2:08
Sleep disorders and neurodegeneration: which comes first?
Ambra Stefani • 23 Jun 2021
Plasma exchange in the treatment landscape of AD 1:46
Plasma exchange in the treatment landscape of AD
Javier Olazarán • 18 Jun 2021
The content of VJNeurology is intended for healthcare professionals